Soluble PD-L1 shows no association to relapse and overall survival in early stage non-small cell lung cancer (NSCLC)
Although in vitro and TCGA data support the suppressive effect of sPD-L1 we were unable to translate this in our clinical setting. These results may be due to the small patient number and their heterogeneity as well as the lack of a standardized sPD-L1 ELISA. Our inconclusive results regarding the value of sPD-L1 in early stage NSCLC warrant assay validation and further investigation in larger (neo-)adjuvant trials.
Authors
- Andreas Pircher (ORCID: https://orcid.org/0000-0002-7747-3012)
- Madita L. Buch (ORCID: https://orcid.org/0009-0003-2983-4957)
- Pia Moser
- Dominik Georg Friedrich Wolf (ORCID: https://orcid.org/0000-0002-4761-075X)
- Finn Mildner
- Florian Augustin (ORCID: https://orcid.org/0000-0002-6785-4241)
- Claudia Manzl (ORCID: https://orcid.org/0000-0001-6269-7585)
- Julia Kargl (ORCID: https://orcid.org/0000-0002-0870-0816)
- Iurii Mykoliuk (ORCID: https://orcid.org/0000-0002-3338-3517)
- Hubert Hackl (ORCID: https://orcid.org/0000-0003-4055-3841)
- Francesco Nocera (ORCID: https://orcid.org/0000-0001-5673-5418)
- Sylvia Raftopoulou (ORCID: https://orcid.org/0000-0002-0871-9437)
- Sieghart Sopper (ORCID: https://orcid.org/0000-0003-2265-1974)
- Gabriele Gamerith
- Florian Kocher (ORCID: https://orcid.org/0000-0002-1027-4609)
- Susanne Sprung
- A Amann (ORCID: https://orcid.org/0000-0001-8514-9223)
- Martina M. Sykora
- Hans Maier
- B. Zelger
- Jörg Lindenmann
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Medical University of Graz (AT)
- Tyrolean Cancer Research Institute (AT)
- Tirol Kliniken (AT)
Publication Details
- Journal
- Lung Cancer
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1016/j.lungcan.2024.107955
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28